{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:05:41Z","timestamp":1784549141750,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019771","name":"European Union's Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rpth.2026.106786","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:30:16Z","timestamp":1781206216000},"page":"106786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunopeptidomics of blood coagulation factor IX: a core peptide derived from the protease domain is promiscuously presented on HLA-DR"],"prefix":"10.1016","volume":"10","author":[{"given":"Michela","family":"Leoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Dierickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Langerhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"van der Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Mul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie J.","family":"Hoogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-2621","authenticated-orcid":false,"given":"Jan","family":"Voorberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106786_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.blre.2017.08.007","article-title":"Haemophilia B: where are we now and what does the future hold?","volume":"32","author":"Dolan","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2026.106786_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221085202","article-title":"International consensus recommendations on the management of people with haemophilia B","volume":"13","author":"Hart","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.106786_bib3","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1080\/13696998.2019.1620246","article-title":"Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP","volume":"22","author":"Davis","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.rpth.2026.106786_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102673","article-title":"Adeno-associated virus-based gene therapy for hemophilia\u2013addressing the gaps","volume":"9","author":"Miesbach","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106786_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13023-024-03181-2","article-title":"A 360-degree perspective on adeno-associated virus (AAV)-based gene therapy for haemophilia: insights from the physician, the nurse and the patient","volume":"19","author":"Miesbach","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rpth.2026.106786_bib6","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (Factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106786_bib7","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106786_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41591-025-04012-y","article-title":"Factor IX-Padua AAV gene therapy in hemophilia B: phases 1\/2 and 3 trials","volume":"32","author":"Xue","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.106786_bib9","doi-asserted-by":"crossref","first-page":"9796","DOI":"10.1073\/pnas.92.21.9796","article-title":"X-ray structure of clotting factor IXa: active site and module structure related to xase activity and hemophilia B","volume":"92","author":"Brandstetter","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.106786_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1050-1738(00)00070-0","article-title":"Activation of factor IX by factor XIa","volume":"10","author":"Gailani","year":"2000","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.rpth.2026.106786_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/iub.70024","article-title":"Blood coagulation factor IX: structure, function, and regulation","volume":"77","author":"Ivanciu","year":"2025","journal-title":"IUBMB Life"},{"key":"10.1016\/j.rpth.2026.106786_bib12","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.3390\/ijms23052762","article-title":"The molecular basis of FIX deficiency in hemophilia B","volume":"23","author":"Shen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rpth.2026.106786_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106786_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0038-1660817","article-title":"Inhibitors in hemophilia B","volume":"44","author":"Santoro","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2026.106786_bib15","first-page":"S125","article-title":"Development of anaphylactic shock in haemophilia B patients with inhibitors","volume":"9","author":"Warrier","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2026.106786_bib16","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1111\/hae.13282","article-title":"Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis","volume":"23","author":"Cugno","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.V98.5.1416","article-title":"Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B","volume":"98","author":"Christophe","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106786_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102887","article-title":"Inhibitor development in nonsevere hemophilia: data from the European Haemophilia Safety Surveillance (EUHASS) registry","volume":"9","author":"Fischer","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106786_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/mgg3.30","article-title":"The CDC hemophilia B mutation project mutation list: a new online resource","volume":"1","author":"Li","year":"2013","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.rpth.2026.106786_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106786_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0091-6749(98)70061-2","article-title":"IgE-mediated allergy and desensitization to factor IX in hemophilia B","volume":"102","author":"Dioun","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rpth.2026.106786_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/hae.12553","article-title":"Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B","volume":"21","author":"Saini","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0952-7915(97)80153-7","article-title":"Origin, maturation and antigen presenting function of dendritic cells","volume":"9","author":"Cella","year":"1997","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.rpth.2026.106786_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1146\/annurev.immunol.22.012703.104538","article-title":"Cell biology of antigen processing in vitro and in vivo","volume":"23","author":"Trombetta","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.rpth.2026.106786_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70075","article-title":"Monocyte-derived dendritic cells: an updated view on an old concept","volume":"336","author":"Segura","year":"2025","journal-title":"Immunol Rev"},{"key":"10.1016\/j.rpth.2026.106786_bib26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2516.2010.02453.x","article-title":"An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact\u00ae), results of phase III and IV clinical studies","volume":"17","author":"Mauser-Bunschoten","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2026.103387","article-title":"A red blood cell-based antigen delivery system to facilitate T cell epitope presentation to promote peripheral tolerance to ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura","volume":"10","author":"Dierickx","year":"2026","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106786_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100563","article-title":"Sensitive, high-throughput HLA-I and HLA-II immunopeptidomics using parallel accumulation-serial fragmentation mass spectrometry","volume":"22","author":"Phulphagar","year":"2023","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.rpth.2026.106786_bib29","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jtha.2024.11.012","article-title":"Exploring red blood cells as an antigen delivery system to modulate the immune response towards FVIII in hemophilia A","volume":"23","author":"Miranda","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106786_bib30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri.2017.143","article-title":"HLA variation and disease","volume":"18","author":"Dendrou","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rpth.2026.106786_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/mas.21905","article-title":"Exploring the dynamic landscape of immunopeptidomics: unravelling posttranslational modifications and navigating bioinformatics terrain","volume":"44","author":"Flender","year":"2025","journal-title":"Mass Spectrom Rev"},{"key":"10.1016\/j.rpth.2026.106786_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.coi.2013.10.005","article-title":"Chemical biology of antigen presentation by MHC molecules","volume":"26","author":"van Kasteren","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.rpth.2026.106786_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101766","article-title":"The biogenesis of the immunopeptidome","volume":"67","author":"Admon","year":"2023","journal-title":"Semin Immunol"},{"key":"10.1016\/j.rpth.2026.106786_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/acs.jproteome.0c00386","article-title":"Mild acid elution and MHC immunoaffinity chromatography reveal similar albeit not identical profiles of the HLA class I immunopeptidome","volume":"20","author":"Sturm","year":"2021","journal-title":"J Proteome Res"},{"key":"10.1016\/j.rpth.2026.106786_bib35","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acs.jproteome.9b00874","article-title":"Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data","volume":"19","author":"Reynisson","year":"2020","journal-title":"J Proteome Res"},{"key":"10.1016\/j.rpth.2026.106786_bib36","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1073\/pnas.1321458111","article-title":"Expanding the detectable HLA peptide repertoire using electron-transfer\/higher-energy collision dissociation (EThcD)","volume":"111","author":"Mommen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.106786_bib37","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.4049\/jimmunol.166.7.4543","article-title":"Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition","volume":"166","author":"Haque","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.rpth.2026.106786_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.12229","article-title":"Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database","volume":"20","author":"Puetz","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2516.1996.tb00006.x","article-title":"Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey","volume":"2","author":"Katz","year":"1996","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/hae.12854","article-title":"Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations","volume":"22","author":"M\u00e5rtensson","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/hae.14139","article-title":"Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)","volume":"27","author":"Shapiro","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2516.2008.01976.x","article-title":"HLA genotype in patients with acquired haemophilia A","volume":"16","author":"Pavlova","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/a-2751-7625","article-title":"Gene therapy of haemophilia: current status and future directions","volume":"46","author":"Miesbach","year":"2026","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2026.106786_bib44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/jcm10020211","article-title":"Inhibitor in congenital factor VII deficiency; a rare but serious therapeutic challenge\u2014a systematic literature review","volume":"10","author":"Ramezanpour","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.106786_bib45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/hae.14944","article-title":"Eptacog beta for the management of patients with haemophilia A and B with inhibitors: a European perspective","volume":"30","author":"Miesbach","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106786_bib46","doi-asserted-by":"crossref","first-page":"13583","DOI":"10.1073\/pnas.241339498","article-title":"Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity","volume":"98","author":"Persson","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rpth.2026.106786_bib47","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.13141","article-title":"Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity","volume":"13","author":"Mahlangu","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106786_bib48","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1538-7836.2012.04667.x","article-title":"Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia","volume":"10","author":"Mahlangu","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106786_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1286","article-title":"Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools","volume":"9","author":"Lamberth","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.rpth.2026.106786_bib50","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1111\/j.1538-7836.2005.01478.x","article-title":"Post-translational modifications in proteins involved in blood coagulation","volume":"3","author":"Hansson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106786_bib51","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41586-024-08484-9","article-title":"Structure and mechanism of vitamin-K-dependent \u03b3-glutamyl carboxylase","volume":"639","author":"Wang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.rpth.2026.106786_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2023.341972","article-title":"Characterization of Gla proteoforms and non-Gla peptides of gamma carboxylated proteins: application to quantification of prothrombin proteoforms in human plasma","volume":"1284","author":"Singh","year":"2023","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.rpth.2026.106786_bib53","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10719-020-09922-2","article-title":"Identification of novel glycosylation events on human serum-derived factor IX","volume":"37","author":"Pegg","year":"2020","journal-title":"Glycoconj J"},{"key":"10.1016\/j.rpth.2026.106786_bib54","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4155\/bio-2017-0086","article-title":"Investigation of O-glycosylation heterogeneity of recombinant coagulation factor IX using LC-MS\/MS","volume":"9","author":"Seo","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.rpth.2026.106786_bib55","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","article-title":"Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics","volume":"14","author":"Purcell","year":"2019","journal-title":"Nat Protoc"},{"key":"10.1016\/j.rpth.2026.106786_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-1759(87)90175-X","article-title":"A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3","volume":"100","author":"Sugawara","year":"1987","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.rpth.2026.106786_bib57","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood-2012-09-456780","article-title":"Preferential HLA-DRB1\u221711-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells","volume":"121","author":"Sorvillo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106786_bib58","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.002246","article-title":"HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII","volume":"10","author":"van Haren","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.rpth.2026.106786_bib59","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Perez-Riverol","year":"2025","journal-title":"Nucleic Acids Res"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:22:04Z","timestamp":1784546524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926034448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2475037926034448"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106786","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunopeptidomics of blood coagulation factor IX: a core peptide derived from the protease domain is promiscuously presented on HLA-DR","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106786"}}